We are live on
!
Find out more
TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Est. Return
18.15%
This Fund
S&P 500
This Quarter
Est. Return
+13.64%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.46B
AUM Growth
+$126M
(+5.4%)
Cap. Flow
-$103M
Cap. Flow
% of AUM
-4.19%
Top 10 Holdings %
Top 10 Hldgs %
40.31%
Holding
211
New
10
Increased
47
Reduced
69
Closed
17
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$23.4M |
| 2 |
Merck
MRK
|
+$20M |
| 3 |
Welltower
WELL
|
+$14.4M |
| 4 |
Cigna
CI
|
+$9.62M |
| 5 |
Eli Lilly
LLY
|
+$9.59M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$25.4M |
| 2 |
Johnson & Johnson
JNJ
|
+$18M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$15M |
| 4 |
AbbVie
ABBV
|
+$14.1M |
| 5 |
Viatris
VTRS
|
+$13.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.43% |
| 2 | Real Estate | 2.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
Waters Corp
WAT
$37.3B
| – | – |
-10,800
| Closed | -$2.04M |
|
|
NVRO
202
DELISTED
NEVRO CORP.
NVRO
| – | – |
-68,760
| Closed | -$2.67M |
|
|
INOV
203
DELISTED
Inovalon Holdings, Inc. Class A Common Stock
INOV
| – | – |
-176,163
| Closed | -$2.5M |
|
|
EIDX
204
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| – | – |
-27,900
| Closed | -$384K |
|
|
DERM
205
DELISTED
Dermira, Inc.
DERM
| – | – |
-161,579
| Closed | -$1.16M |
|
|
ACHN
206
DELISTED
Achillion Pharmaceuticals
ACHN
| – | – |
-318,833
| Closed | -$507K |
|
|
ONCE
207
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| – | – |
-10,772
| Closed | -$422K |
|
|
NITE
208
DELISTED
Nightstar Therapeutics plc American Depositary Shares
NITE
| – | – |
-98,929
| Closed | -$1.14M |
|
|
LOXO
209
DELISTED
Loxo Oncology, Inc
LOXO
| – | – |
-24,595
| Closed | -$3.44M |
|
|
SHPG
210
DELISTED
Shire pic
SHPG
| – | – |
-36,216
| Closed | -$6.3M |
|
Similar funds
EST
VIA
AWS
JP
VCM
FCFS
FCB
BWM
Tekla Capital Management's Q1 2019 Portfolio in Review
As of Q1 2019, Tekla Capital Management held 211 positions worth $2.46B, up 5.4% from $2.34B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Tekla Capital Management withdrew a net $103M in Q1 2019, closing 17 positions and reducing 69 holdings. Its most notable exit was Shire pic, an estimated $6.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 94% a quarter earlier, followed by Real Estate.
Against the trend, Tekla Capital Management opened a new position in Bio-Techne worth $4.31M.
- Tekla Capital Management's largest Q1 2019 buy was Bio-Techne: 86,804 shares worth $4.31M.
- Tekla Capital Management added most to Pfizer in Q1 2019, an estimated $23.4M increase.
- Tekla Capital Management's biggest Q1 2019 reduction was Biogen, cutting an estimated $25.4M.
- Tekla Capital Management fully exited Shire pic in Q1 2019, selling an estimated $6.3M.
- Tekla Capital Management's ten largest holdings make up 40% of its $2.46B portfolio in Q1 2019.
- Tekla Capital Management opened 10 new positions and closed 17 in Q1 2019.
- Tekla Capital Management's portfolio value rose 5.4% quarter-over-quarter to $2.46B.
Based on Tekla Capital Management's 13F filing for Q1 2019, filed 14 May 2019.